Replimune Group, Inc.
REPL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737953
In the last 90 days, Replimune Group, Inc. insiders filed 0 open-market purchases and 5 sales; 199 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Replimune Group, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 180
- +17 vs. Q4 2025
- Shares held
- 81.1M
- +5.13M (+6.7%) vs. Q4 2025
- Total value
- $619.2M
- −$119.3M (−16.2%) vs. Q4 2025
- New holders
- 46
- 62 more added
- Sold out
- 29
- 49 more reduced
2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting REPL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 199 | $1.06B |
| Q1 2026 | 180 | $619.2M |
| Q4 2025 | 165 | $775.2M |
| Q3 2025 | 163 | $347.5M |
| Q2 2025 | 175 | $752.1M |
| Q1 2025 | 167 | $799.3M |
| Q4 2024 | 157 | $943.2M |
| Q3 2024 | 144 | $766.7M |
| Q2 2024 | 149 | $638.1M |
| Q1 2024 | 150 | $547.8M |
| Q4 2023 | 140 | $556.8M |
| Q3 2023 | 127 | $970.9M |
| Q2 2023 | 141 | $1.27B |
| Q1 2023 | 140 | $949.0M |
| Q4 2022 | 135 | $1.31B |
| Q3 2022 | 106 | $703.9M |
| Q2 2022 | 102 | $700.2M |
| Q1 2022 | 107 | $665.0M |
| Q4 2021 | 99 | $1.05B |
| Q3 2021 | 101 | $1.05B |
| Q2 2021 | 110 | $1.34B |
| Q1 2021 | 108 | $1.06B |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Replimune Group, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| J. Goldman & Co LP | 0 | $0 | 0.00% | −15,595−100.0% | Sold out |
| Hamilton Capital Partners, LLC | 0 | $0 | 0.00% | −11,492−100.0% | Sold out |
| Entropy Technologies, LP | 0 | $0 | 0.00% | −10,486−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −2,174−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Pinnacle Wealth Planning Services, Inc. | 0 | $0 | 0.00% | −137−100.0% | Sold out |
| UMA Financial Services, Inc. | 0 | $0 | 0.00% | −111−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −19−100.0% | Sold out |
| Vestor Capital, LLC | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |
| Comerica Bank | – | – | – | – | Not filed |